Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Q BioMed's Average Total Inventories for the quarter that ended in Feb. 2023 was $0.00 Mil. Q BioMed's Revenue for the
three
months ended in Feb. 2023 was $0.00 Mil.
Q BioMed's Inventory-to-Revenue for the quarter that ended in Feb. 2023
declined
from Nov. 2022 (1.77) to Nov. 2022 (0.00)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Q BioMed's Days Inventory for the
three
months ended in Feb. 2023 was 0.00.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Q BioMed Inventory-to-Revenue Historical Data
The historical data trend for Q BioMed's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Q BioMed's Inventory-to-Revenue
For the Biotechnology subindustry, Q BioMed's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q BioMed's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q BioMed's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Q BioMed's Inventory-to-Revenue falls into.
Q BioMed Inventory-to-Revenue Calculation
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Q BioMed's Inventory-to-Revenue for the fiscal year that ended in Nov. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Q BioMed's Days Inventory for the
three
months ended in Feb. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q BioMed Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Q BioMed's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
QBIO has been successfully added to your 